First patient dosed in the PiNACLE – H2H Ph 3 trial of rondecabtagene autoleucel (ronde-cel or LYL314) vs liso-cel or axi-cel in 2L R/R LBCL February 17, 2026
CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors February 17, 2026
RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic NSCLC February 17, 2026
KEYTRUDA and KEYTRUDA QLEX, Plus Paclitaxel ± Bevacizumab, Approved for 2L/3L PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma February 17, 2026
Tempest plans to prioritize development of clinical-stage dual-targeting CD19/BCMA CAR-T program, TPST-2003 February 17, 2026
CARsgen Signs Strategic Cooperation Agreements to Expand CAR-T Commercial Manufacturing Base in China February 17, 2026
First Patient Enrolled in Global Ph 1 Trial of AN9025 for Solid Tumors Harboring RAS Mutations February 17, 2026
Encouraging Patient Survival Observations Reported in Ovarian Cancer Lira-cel CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation February 17, 2026
Ph 3 LIBRETTO-432 trial of Retevmo (selpercatinib) met primary endpoint of EFS in patients with early-stage (II-IIIA) RET fusion-positive NSCLC February 17, 2026
FDA cleared IND application for NPX372 in B7-H7–expressing solid tumors, including lung adenocarcinoma, RCC, and pancreatic adenocarcinoma February 17, 2026
US FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer February 17, 2026
